Abstract | PURPOSE: METHODS: Tumours were induced in female Wistar rats by injection of N-nitroso-N- methylurea at 100 mg/kg subcutaneously. A clinically relevant single dose of DMXAA (1,800 mg/m(2)) was given to animals when tumours were measurable. Tumour volume, extent of necrosis and cytokine profiles were measured. RESULTS: Compared with the control group, DMXAA treatment significantly delayed tumour doubling time and extended the time from treatment to euthanasia. Four of five DMXAA-treated animals showed necrosis involving 3.7-41.2% of the area of the tumour section at 24 h compared with none of four control animals (P < 0.028, Chi-square test). Intratumoural levels of TNFalpha, IL-6, VEGF and IL-1alpha were increased 4 h after DMXAA treatment. CONCLUSIONS: This study shows for the first time that DMXAA has significant in vivo antitumour activity against non-transplanted autochthonous tumours and in a host species other than the mouse.
|
Authors | Johnson J Liu, Lai-Ming Ching, Michael Goldthorpe, Rachel Sutherland, Bruce C Baguley, James A Kirker, Mark J McKeage |
Journal | Cancer chemotherapy and pharmacology
(Cancer Chemother Pharmacol)
Vol. 59
Issue 5
Pg. 661-9
(Apr 2007)
ISSN: 0344-5704 [Print] Germany |
PMID | 16944150
(Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
|
Chemical References |
- Antineoplastic Agents
- Carcinogens
- Cytokines
- Xanthones
- vadimezan
- Methylnitrosourea
|
Topics |
- Animals
- Antineoplastic Agents
(therapeutic use)
- Apoptosis
(drug effects)
- Carcinogens
- Cytokines
(biosynthesis)
- Female
- Immunoassay
- In Situ Nick-End Labeling
- Mammary Neoplasms, Experimental
(chemically induced, drug therapy, pathology)
- Methylnitrosourea
- Rats
- Xanthones
(therapeutic use)
|